BioCentury
ARTICLE | Translation in Brief

To screen and protect

Taking TKIs to task for cardiotoxicity

March 9, 2017 10:16 PM UTC

A Science Translational Medicine study has established a quantitative metric of drug cardiotoxicity in human-derived cardiomyocytes, and identified insulin-based strategies to alleviate the cardiotoxicity of certain tyrosine kinase inhibitors (TKIs). Study leader Joseph Wu said the metric could help pharmas catch and counter cardiotoxicity early in drug development, "rather than finding out post-marketing."

Wu is director of the Stanford Cardiovascular Institute and a professor in the departments of medicine and radiology at the Stanford University School of Medicine. He is also co-founder and director of Stem Cell Theranostics Inc., which develops patient-derived induced pluripotent stem (iPS) cells to predict cardiotoxicity and cardiovascular drug efficacy, though the company was not involved in this study...